Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
HRD testing
Description:
Diagnostic testing that assesses homologous recombination deficiency in tumors, particularly to inform cancer treatment decisions.
Primary topic:
PARP inhibition in cancer therapy (50%)
Related topics:
PARP inhibition in cancer therapy (50%),
BRCA gene mutations in cancer (27%),
Ovarian cancer diagnosis and treatment (13%)
OpenAlex ID:
keywords/hrd-testing
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
2020
·
R.E. Miller
, A. Leary
, et al.
·
Annals of Oncology
·
535
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
2021
·
N.Y.L. Ngoi
, D.S.P. Tan
·
ESMO Open
·
154
Homologous recombination proficiency in ovarian and breast cancer patients
2021
·
Justin Fortune Creeden
, Nisha S. Nanavaty
, et al.
·
BMC Cancer
·
106
PDF
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
2022
·
Lola Paulet
, Alexis Trecourt
, et al.
·
European Journal of Cancer
·
63
PDF
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics
2025
·
Andréa Witz
, Julie Dardare
, et al.
·
Biomarker Research
·
62
PDF
Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches
2023
·
Alessandro Mangogna
, Giada Munari
, et al.
·
Journal of Personalized Medicine
·
62
Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation
2021
·
Marjolijn M. Ladan
, Dik C. van Gent
, et al.
·
Cancers
·
54
PDF
How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
2024
·
Martina Arcieri
, Veronica Tius
, et al.
·
Frontiers in Oncology
·
52
PDF
Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
2024
·
Federica Guffanti
, Ilaria Mengoli
, et al.
·
Frontiers in Oncology
·
46
PDF
RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
2022
·
Lise M. van Wijk
, Andreea B. Nilas
, et al.
·
Expert Review of Molecular Diagnostics
·
45
PDF
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023
·
Raphaël Leman
, Etienne Muller
, et al.
·
Clinical Cancer Research
·
38
PDF
Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer
2023
·
Florian Heitz
, Beyhan Ataseven
, et al.
·
Cancers
·
36
PDF
HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients
2023
·
Lei Li
, Yu Gu
, et al.
·
npj Precision Oncology
·
28
PDF
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial
2024
·
Cristin Roma
, Riziero Esposito Abate
, et al.
·
European Journal of Cancer
·
26
The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
2022
·
Vilma Pacheco-Barcia
, Andrés Muñoz
, et al.
·
Cancers
·
25
Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape
2024
·
Gordon R. Daly
, Sindhuja Naidoo
, et al.
·
Current Oncology Reports
·
21
201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative
2021
·
E Pujade-Lauraine
, Y Christinat
, et al.
·
International Journal of Gynecological Cancer
·
21
PDF
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer—Development of Recommendations for Optimal Assay Performance
2024
·
Marcel Romey
, Fiona Rodepeter
, et al.
·
Modern Pathology
·
18
PDF
Recommendations for Clinical Molecular Laboratories for Detection of Homologous Recombination Deficiency in Cancer
2025
·
Susan J. Hsiao
, Destin Black
, et al.
·
Journal of Molecular Diagnostics
·
15
A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis
2023
·
Rodrigo Guarischi-Sousa
, José Eduardo Kroll
, et al.
·
Diagnostics
·
13
PDF
The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers
2025
·
Qiuyang Xu
, Yuanjia Wen
, et al.
·
Biomarker Research
·
12
PDF
Evaluative Methodology for HRD Testing: Development of Standard Tools for Consistency Assessment
2025
·
Zheng Jia
, Yaqing Liu
, et al.
·
Genomics Proteomics & Bioinformatics
·
9
Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy
2024
·
Carla Rognoni
, Domenica Lorusso
, et al.
·
Advances in Therapy
·
7
PDF
Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion
2022
·
I Vergote
, H Denys
, et al.
·
Facts Views and Vision in ObGyn
·
5
PDF
Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.
2023
·
Anupama Vasudevan
, Sandy English
, et al.
·
Journal of Clinical Oncology
·
4
Show more works
View as search
Works count:
99
Citation count:
1,498
Year
Topic
Type